All-or-Nothing Bet on New Bristol Myers Drugs Faces First Test

March 18, 2020

An upcoming U.S. regulatory decision for Bristol Myers Squibb Co.’s multiple sclerosis treatment marks the first of three key milestones that will dictate the fate of its all-or-nothing payment to former Celgene Corp. investors.

Related Stories